Pain being trained on Riva!!!

Quote
Anonymous said:
That all makes perfect sense except the 30 day timeline. End of the quarter (June) would make more sense. Perhaps you mean the changes will be rolled out to upper management, then mid-management, then the field. Your post suggests a possible head-count reduction or does it suggest an expansion??? Do you know if pods are back on the table? Thanks for what seems like an accurate or at least honest post.
Click to expand...

There are few different scenarios being discussed and ready to go. All they need is the trigger to be pulled. Trust me, this can go at any minute and the home office has developed very good skills over the years of keeping only a small number of people working with ZS who are tight lipped. After all the downsize practice since 2004, they've become good at deception.

"No, things are alright, there are no plans to downsize" - - - Then WHAM! Good night all.
 




H.O.

The plan is to try and keep head count neutral. With that said there is a lot on the line with Rivo and NucER. We are not getting the info we want, the good news is we are not getting bad news either. Every one is waiting. I said head count neutral? This includes the 240plus for CV. We have over 60-100 AIGI on contract, I lost count They will be adjusting AI/GI/Pain to retail and there will not be pods. they are going to have to reduce some area or at least move around head count to account for the CV team. The good news for you in the field is there was a lot of push back to hiring CV from out side at the rep level and they have made the decision to hire from AIGI/PAIN first before going outside. that should help minimize head count loss to AIGI/Pain. The other insight I can give you is there will be a reduction in Managers on the AIGI/Pain (Retail) Districts will be larger 10-12 reps per vs the 7-9 we are currently at. You are basically looking at 600 retail and 240-260 CV and a increase of 20 Hospital, so if you take out the contract reps it is head count neutral.
 




Anonymous said:
H.O.

The plan is to try and keep head count neutral. With that said there is a lot on the line with Rivo and NucER. We are not getting the info we want, the good news is we are not getting bad news either. Every one is waiting. I said head count neutral? This includes the 240plus for CV. We have over 60-100 AIGI on contract, I lost count They will be adjusting AI/GI/Pain to retail and there will not be pods. they are going to have to reduce some area or at least move around head count to account for the CV team. The good news for you in the field is there was a lot of push back to hiring CV from out side at the rep level and they have made the decision to hire from AIGI/PAIN first before going outside. that should help minimize head count loss to AIGI/Pain. The other insight I can give you is there will be a reduction in Managers on the AIGI/Pain (Retail) Districts will be larger 10-12 reps per vs the 7-9 we are currently at. You are basically looking at 600 retail and 240-260 CV and a increase of 20 Hospital, so if you take out the contract reps it is head count neutral.
Click to expand...

And paid for through which revenue stream? Is it the $6B in cash J&J is sitting on? You can't lose a product like Levaquin and hold headcount on the promise of two drugs that haven't been released yet. Not to mention the horrible track record this company has with launching products in a generic market with no contracting. Just think back to UER, Nucynta IR, Invega. The last successful launch was LEV and now its going bub-bye.
 




Anonymous said:
H.O.

The plan is to try and keep head count neutral. With that said there is a lot on the line with Rivo and NucER. We are not getting the info we want, the good news is we are not getting bad news either. Every one is waiting. I said head count neutral? This includes the 240plus for CV. We have over 60-100 AIGI on contract, I lost count They will be adjusting AI/GI/Pain to retail and there will not be pods. they are going to have to reduce some area or at least move around head count to account for the CV team. The good news for you in the field is there was a lot of push back to hiring CV from out side at the rep level and they have made the decision to hire from AIGI/PAIN first before going outside. that should help minimize head count loss to AIGI/Pain. The other insight I can give you is there will be a reduction in Managers on the AIGI/Pain (Retail) Districts will be larger 10-12 reps per vs the 7-9 we are currently at. You are basically looking at 600 retail and 240-260 CV and a increase of 20 Hospital, so if you take out the contract reps it is head count neutral.
Click to expand...

Dearest Home Office,
So appreciate the inside scoop but there's like 1500 Ortho-McN retail reps in the field NOW (if you count Hospital). I hear ya saying that it will be 600. How's that neutral ???

Warmest regards,
Another worried AI-GI rep
 








HO

Retail will only consist of AI/GI/Pain. Hospital is on the Institutional side. OBI is also a different division. The 1500 you mention is the head count responsible for selling Nucynta IR currently and it includes OBI AI/GI, Pain, Hospital. Head count neutral is looking only at AI/GI/Pain minus the contract. Contract sales people do not count towards head count. The total head count is some where in the realm of 800 or so. I am not 100% on the exact number of contract sales rep. Minus the contract reps from the total number of territories on both AI/GI/Pain. That is the head count currently. There will be some downsizing with AI/GI/Pain, but the thought is that a lot of the CV territories will be filled internally with AI/GI/Pain reps, thus reducing the number of people losing there job and it will officially not be a downsizing. If you are one of the AI/GI/pain reps that is out of a territory it will not matter what the official name of it is. They are projecting less than 5% of territory reps being affected.
 












Hey H.O.,
Thank you for giving an honest assessment of what's around the corner. I am so tired of seeing these cryptic "Paul Revere" messages that end up never happening. I hope what you predict is true, and that riva gets approval quickly. Keep us informed!

Thanks,
A Worried AI/GI Rep
 




Anonymous said:
J&J loves specialty sales forces and most of the new products fit in that area. AI/GI has contract sales reps. Could be that primary care is going to contract sales reps!
Click to expand...

This is so true. Don't you remember how the PriCrapa name originated?
PriCara- "The primary care specialists" What an absolute joke. I use to gag when I had to say I was from PriCrapa.
The doctors would look at use like...."you've got to be fucking kidding"
 




Anonymous; said:
Hey H.O.,
Thank you for giving an honest assessment of what's around the corner. I am so tired of seeing these cryptic "Paul Revere" messages that end up never happening. I hope what you predict is true, and that riva gets approval quickly. Keep us informed!

Thanks,
A Worried AI/GI Rep
Click to expand...

Get your worried ass to work. What a fucking dork! I predict that you can't sell shit.
 








The good news for the jnj pharma reps and managers is that there will be a consolidation with the biotech divisions within the next two years. Expect more of the pharma managers and reps moving over and working at the biotech divisions and vice-versa. JnJ is too diversified to keep the same people at the same company for so long. Leadership has realized things need to be switched around and shaken up. Expect a nice bump in salary when we merge with the biotech divisions.
 








Anonymous said:
The good news for the jnj pharma reps and managers is that there will be a consolidation with the biotech divisions within the next two years. Expect more of the pharma managers and reps moving over and working at the biotech divisions and vice-versa. JnJ is too diversified to keep the same people at the same company for so long. Leadership has realized things need to be switched around and shaken up. Expect a nice bump in salary when we merge with the biotech divisions.
Click to expand...

Source??
 




My dm keeps mentioning the consolidation of the pharma and divisions as well. Said it's evident due to co-promotions with the two divisions and quintiles contract reps for simponi, remicade, nucynta, and riva. He doesn't know when but says changes are coming soon and we all better be ready to interview for our positions if we want to stay with the new j&j biopharma company. Is this a scare tactic by the dms to work harder or the truth?
 




Anonymous said:
H.O.

The plan is to try and keep head count neutral. With that said there is a lot on the line with Rivo and NucER. We are not getting the info we want, the good news is we are not getting bad news either. Every one is waiting. I said head count neutral? This includes the 240plus for CV. We have over 60-100 AIGI on contract, I lost count They will be adjusting AI/GI/Pain to retail and there will not be pods. they are going to have to reduce some area or at least move around head count to account for the CV team. The good news for you in the field is there was a lot of push back to hiring CV from out side at the rep level and they have made the decision to hire from AIGI/PAIN first before going outside. that should help minimize head count loss to AIGI/Pain. The other insight I can give you is there will be a reduction in Managers on the AIGI/Pain (Retail) Districts will be larger 10-12 reps per vs the 7-9 we are currently at. You are basically looking at 600 retail and 240-260 CV and a increase of 20 Hospital, so if you take out the contract reps it is head count neutral.
Click to expand...

Any updates HO? Loving the info about the larger DM responsibility even though there are rumors of "micro" territories with DM responsibility for only 6 reps per district. Any insight as to timing? Is it status quo for one more painful quarter? Thanks for any info.
 




Top Bottom
Back
Quote